MedTrace Logo

The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

NCT00857350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-07-22

No results posted yet for this study

Summary

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses:

1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.
2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Conditions

  • HIV Positive
  • Opioid Dependence
  • Opioid Agonist Treatment
  • HIV Infections

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • David Fiellin, MD · Yale University

  • Jeanette Tetrault, MD · Yale University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-06-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857350 on ClinicalTrials.gov